336 related articles for article (PubMed ID: 31663374)
1. Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?
Layne KA; Wood DM; Dargan PI
Clin Toxicol (Phila); 2020 Mar; 58(3):151-160. PubMed ID: 31663374
[No Abstract] [Full Text] [Related]
2. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
[TBL] [Abstract][Full Text] [Related]
3. High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification.
Barbieri S; Schroeder C; Froehlich JM; Pasch A; Thoeny HC
Contrast Media Mol Imaging; 2016 May; 11(3):245-50. PubMed ID: 26929131
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
Layne KA; Dargan PI; Archer JRH; Wood DM
Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Patient with Reported Gadolinium-Associated Illness.
Lyapustina T; Goldfine C; Rhyee S; Babu KM; Griswold MK
J Med Toxicol; 2019 Jan; 15(1):36-44. PubMed ID: 30499040
[TBL] [Abstract][Full Text] [Related]
6. Brain gadolinium deposition after administration of gadolinium-based contrast agents.
Kanda T; Oba H; Toyoda K; Kitajima K; Furui S
Jpn J Radiol; 2016 Jan; 34(1):3-9. PubMed ID: 26608061
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium Retention and Toxicity-An Update.
Ramalho M; Ramalho J; Burke LM; Semelka RC
Adv Chronic Kidney Dis; 2017 May; 24(3):138-146. PubMed ID: 28501075
[TBL] [Abstract][Full Text] [Related]
8. Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses: Current Status of Preclinical and Clinical Studies.
Parillo M; Mallio CA; Van der Molen AJ; Rovira À; Ramalho J; Ramalho M; Gianolio E; Karst U; Radbruch A; Stroomberg G; Clement O; Dekkers IA; Nederveen AJ; Quattrocchi CC;
Invest Radiol; 2023 Aug; 58(8):530-538. PubMed ID: 37185158
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.
Perazella MA
Curr Drug Saf; 2008 Jan; 3(1):67-75. PubMed ID: 18690983
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.
Rogosnitzky M; Branch S
Biometals; 2016 Jun; 29(3):365-76. PubMed ID: 27053146
[TBL] [Abstract][Full Text] [Related]
11. Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.
Murata N; Gonzalez-Cuyar LF; Murata K; Fligner C; Dills R; Hippe D; Maravilla KR
Invest Radiol; 2016 Jul; 51(7):447-53. PubMed ID: 26863577
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium deposition in the brain.
Kanda T; Nakai Y; Oba H; Toyoda K; Kitajima K; Furui S
Magn Reson Imaging; 2016 Dec; 34(10):1346-1350. PubMed ID: 27613998
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium deposition disease: Initial description of a disease that has been around for a while.
Semelka RC; Ramalho J; Vakharia A; AlObaidy M; Burke LM; Jay M; Ramalho M
Magn Reson Imaging; 2016 Dec; 34(10):1383-1390. PubMed ID: 27530966
[TBL] [Abstract][Full Text] [Related]
14. Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of gadolinium contrast.
Roberts DR; Holden KR
Brain Dev; 2016 Mar; 38(3):331-6. PubMed ID: 26345358
[TBL] [Abstract][Full Text] [Related]
15. Gadolinium-based contrast agents in children.
Rozenfeld MN; Podberesky DJ
Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
[TBL] [Abstract][Full Text] [Related]
16. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.
Bhave G; Lewis JB; Chang SS
J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232
[TBL] [Abstract][Full Text] [Related]
17. Where does the gadolinium go? A review into the excretion and retention of intravenous gadolinium.
Sharma P; Cheng J; Coulthard A
J Med Imaging Radiat Oncol; 2023 Oct; 67(7):742-752. PubMed ID: 37665796
[TBL] [Abstract][Full Text] [Related]
18. [Nephrogenic systemic fibrosis].
Breitschaft A; Stahlmann R
Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents.
Rees JA; Deblonde GJ; An DD; Ansoborlo C; Gauny SS; Abergel RJ
Sci Rep; 2018 Mar; 8(1):4419. PubMed ID: 29535330
[TBL] [Abstract][Full Text] [Related]
20. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
Holowka S; Shroff M; Chavhan GB
Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
